Evidence map›Paper›PMID 40685851›Full record

ReviewAdvanced healthcare materials2025

A Comprehensive Review of Clinical Studies on Bacterial Cellulose: From the Earliest Uses to Contemporary Innovations.

Thomas Meslier, Justin Christopher D'Antin, Gemma Julio, Anna Roig

Abstract readReview
In one paragraph

Review in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Probiotic-Based Materials as Living Therapeutics.Advanced materials (Deerfield Beach, Fla.) · 2026
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Thomas MeslierInstitut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, Bellaterra, Catalonia, E-08193, Spain.ORCID 0000-0001-6012-8944
Justin Christopher D'AntinCentro de Oftalmología Barraquer, Barcelona, Catalonia, E-08021, Spain.ORCID 0000-0002-6255-2498
Gemma JulioCentro de Oftalmología Barraquer, Barcelona, Catalonia, E-08021, Spain.ORCID 0000-0003-4666-1288
Anna RoigInstitut de Ciència de Materials de Barcelona (ICMAB-CSIC), Campus UAB, Bellaterra, Catalonia, E-08193, Spain.ORCID 0000-0001-6464-7573

Funding

Agència de Gestió d'Ajuts Universitaris i de Recerca 2019LLAV00046Agència de Gestió d'Ajuts Universitaris i de Recerca 2021PRO00204Agència de Gestió d'Ajuts Universitaris i de Recerca 2021SGR00446Agència de Gestió d'Ajuts Universitaris i de Recerca 2023INNOV00044ERDF A way of making EuropeMinisterio de Ciencia e Innovación CEX2023001263-SMinisterio de Ciencia e Innovación PID2021-122645OBI00
6 · The paper itself

Abstract

Bacterial cellulose (BC), a biopolymer produced by Gram-negative bacteria such as those from the Komagataeibacter genus, has emerged as a promising material in biomedical applications due to its exceptional purity, biocompatibility, mechanical strength, versatility in sterilization, biodegradability, and sustainable production. This comprehensive review traces the evolution of BC-based medical products from their initial development in the 1980s to present-day innovations, highlighting the progression of clinical evidence supporting their use. Early clinical studies primarily focused on BC as a temporary skin substitute for burns and ulcers. Over time, the scope of BC applications expanded to include dural defect repair, tympanic membrane reconstruction, and fetal surgery for spina bifida. The quality of clinical evidence has improved, with recent years seeing an increase in randomized controlled trials and larger patient cohorts. Several BC-based products are already commercially available, supported by regulatory approvals and a growing body of clinical data. This review seeks to serve as a valuable resource by providing an exhaustive recapitulation of published clinical studies on BC-based medical devices encompassing 3,857 subjects and offering insights into their efficacy, safety, and regulatory considerations. The review outlines future research directions to validate BC's potential across a wide range of in vivo biomedical applications.

Indexed as

BacteriaBiocompatible MaterialsCelluloseAnimalsHumansSkin, ArtificialBiocompatible MaterialsCellulosebacterial celluloseclinical investigationmedical devicemedical device regulationnanocomposites

Identifiers

PMID40685851
PMCPMC12538539

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.